Dentists complained about problems with the supply of the popular painkiller Ubistezin, cement, burs and other medical supplies, and some foreign drugs. It is reported by RBC. Difficulties with procurement occur due to the departure of foreign manufacturers and problems with logistics.
The manufacturer of Ubistezin, the American company 3M, announced its withdrawal from the Russian market in the spring of 2022. Russian analogues are significantly worse than the American drug, says Svyatoslav Koba, Medical Director of Dental Fantasy and Belgravia Dental Studio. At the same time, there are no difficulties with Russian painkillers and the Spanish Artikain Inibsa.
In 2022, the market received 93.9 thousand packages of Ubistezin in the amount of 369 million rubles, and this is 70% less than in 2021, if counted in packages, and 60% less, if counted in ruble terms, said Nikolai Bespalov, Development Director of the analytical company RNC Pharma.
In addition, Vitremer cement has ceased to be supplied to Russia, they say in clinics. It has no analogues on the Russian market. There are also problems with the supply of dental burs and cutters. There is a shortage of handpiece sprays, hygiene powder, handpiece spare parts and installations.
“Certain inconveniences are also associated with the absence of grinding discs from the 3M company, which left the Russian market. The domestic analogue is inferior to the imported material in terms of quality. The abrasiveness of the discs is low, and for primary grinding of the filling, not one disc is needed, but two or more, which increases the cost of treatment and increases its duration, ”said Irina Lukashenok, dentist-therapist at the First Family Clinic of St. Petersburg.